A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
In brief
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Key facts
- Study ID
- NCT04104776
- Run by
- Novartis Pharmaceuticals
- People needed
- 300
- Starts
- 2019-09-18
- Expected to finish
- 2030-02-27
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- IRCCS Policlinico Universitario Fondazione Agostino Gemelli — Roma, Italy (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- Institut Cancerologie de Strasbourg — Strasbourg, France (enrolling)
- Humanitas San Pio X — Milan, Italy (enrolling)
- Uniwersyteckie Centrum Kliniczne GUMed — Gdansk, Poland (enrolling)
- Gachon University Gil Medical Center — Incheon, South Korea (enrolling)
- Centre Leon Berard — Lyon, France (enrolling)
- CHU Nantes Hopital Nord Laennec — Saint-Herblain, France (enrolling)
- CLCC Institut Gustave Roussy — Villejuif, France (enrolling)
- European Institute of Oncology (IEO), IRCCS ( Department of Urogenital and Head-and-Neck Medical Oncology) — Milan, Italy (enrolling)
- Massachusetts General Hospital (MGH) — Boston, Massachusetts, United States (enrolling)
- IRCCS Istituto Clinico Humanitas - Research Hospital — Rozzano, Italy (enrolling)
- University of Chicago — Chicago, Illinois, United States (enrolling)
- University Teaching Hospital — Poznan, Poland (enrolling)
- Emory University School of Medicine — Atlanta, Georgia, United States (enrolling)
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- CHU Nantes Hopital Hotel Dieu — Nantes, France (enrolling)
- CHU Nantes Hopital Hotel Dieu — Nantes, France (enrolling)
- University of Virginia Health System (UVAHS) — Charlottesville, Virginia, United States (enrolling)
- Swedish Cancer Institute — Seattle, Washington, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- National Cancer Institute, IRCCS — Milan, Italy (enrolling)
- CLCC Institut Bergonie — Bordeaux, France (enrolling)
- Centre Oscar Lambret — Lille, France (enrolling)
- Yonsei Univ Health System YUCM — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.